Background: We evaluated the 180-day results of percutaneous coronary intervention (PCI) for recent 3.7 year period in a high-volume tertiary center. Methods: From November 2005 to June 2009, we retrospectively evaluated 1,826 patients who underwent PCI for acute myocardial infarction (AMI). Patients treated with thrombolytic therapy were excluded, and 1,686 patients (1,200 male; mean age 64.0 짹 12.4 years) were included in the final analysis. 180-day clinical outcomes and angiographic results were recorded. Results: On admission, 48.5% of the patients had hypertension, 29.1% had diabetes, 49.5% had anterior myocardial infarction, and 4.9% had cardiogenic shock. Infarct-related artery was the left anterior descending artery in 47%, and multivessel disease was present in 51.6%. Type C coronary lesion according to the ACC/AHA classification decreased significantly (36.9, 28.6, 19.6, and 21.3%, from 2006 to 2009 years, linear p<0.001). PCI involved balloon dilatation (6.1%) and stent implantation (93.9%). 79% of the patients were treated with drug-eluting stents. The mean length and diameter of the stents were 23.9 짹 6.1 and 3.2 짹 0.4 mm, respectively. 92% of the patients were treated at the coronary care unit, and the mean stay was 3.2 짹 4.0 days. Life saving medications during hospitalization included aspirin (99.3%), clopidogrel (99.4%), beta-blocker (87.3%), renin-angiotensin-aldosterone system blocker (84.8%), and lipid-lowering drug (77.1%). There were 63 (3.7%) in-hospital deaths. During 180-day follow-up period, all-cause mortality occurred in 124 patients (7.6%). Other major cardiac events were re-myocardial infarction (0.4%), re-PCI(10%), and coronary artery bypass grafting (0.2%). Conclusion: PCI is an effective method in achieving complete revascularization of the infarct-related artery. More intensive treatment including life-saving medications for AMI may result in better clinical outcomes.